🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

See also: "Psychedelic-assisted psychotherapy: Where is the psychotherapy research?" link.springer.com/article/10.100…

NEW: On Friday, in a decision that would have been stunning just six months ago, the Food and Drug Administration decided against approving MDMA-assisted therapy for PTSD. It's not the FDA's fault. It's because of bad science. Katie MacBride @msmacb on bluesky breaks down why slate.com/technology/202…

Know someone with back pain? We're recruiting for a study of #psilocybin for chronic low back pain! screen: stanforduniversity.qualtrics.com/jfe/form/SV_da… Please RT ........................................... Close collab w TrPR Program @ UCSF Josh Woolley MD/PhD Michael Silver Berkeley Neuroscience #ChronicPain

Good thread from Aaron D. Cherniak who is well worth a follow

“Compared to their representation in the US and nonpsychedelic clinical trials, Black/African American (12.2%) and Hispanic/Latino participants (7.2%) were significantly underrepresented in PAT RCTs. MDMA trials enrolled more diverse participant samples than psilocybin trials.”

Because I agree with the FDA’s decision not to approve the MDMA-AT application & in the last 24hrs, a person (man) with an MD/PhD has: 1. Questioned my degree, training, expertise & ability to independently interpret data (3x) And told me I’m: 2. Brainwashed & uninformed (3x)

Tired of the same arguments about unmasking in #MDMA / #psychedelic trails? Bored of people throwing around unmasking without quantitative analysis? Unsure of what is even unmasking bias? If you answered yes to any, this is your lucky day! In this short🚨preprint🚨, we

Timely and important commentary "Monkeys will be necessary for the discovery, development, and testing of disease-modifying treatments.." because well, let's be honest that curing depression, autism, loneliness, addiction, etc in mice has not led to any truly novel treatments

Great paper on important topic: viability of for-profit commercial models for psychedelic therapy

Harder to prepare than any grant.

As the author of this PDF, it's been interesting seeing people guess at the rationale behind its design. However, the rationale had nothing to do with theory vs practice, and everything to do with pragmatically coping with an unaccommodated disability in academia. (1/16)

The incentive to obscure or deny that psychedelic therapy- including dose sessions- is *psychotherapy* is above all a financial one. "Psych support" = more easily scalable bc providers need less qualifications/training & lower pay for providers. Bad for pts and bad for clinicians

bsky.app/profile/trpr-u… moving to where the skies are blue. Saving eg MySpace was not a reasonable goal. Sometimes letting something die is required for rebirth. We are the product. Our actions are the new oil.

We've launched a new clinical trial exploring the efficacy and mechanisms of psilocybin therapy for depression in Parkinson's disease! #ParkinsonsDisease #PD #PsychedelicResearch #DepressionResearch #Neuroscience psychedelics.ucsf.edu/#Studies

New paper posted on the good place bsky.app/profile/stepha…

Huge Co-1st/Corresponding author paper just published in JAMA Psychiatry ! I just can't thank our team enough for their unwavering support on this project. Modifying Informed Consent to Help Address Functional Unmasking in Psychedelic Clinical Trials jamanetwork.com/journals/jamap…

Can modifications of informed consent address functional unmasking in RCTs of psychedelic therapy? For answer, see latest TrPR Program @ UCSF paper with the amazing D. Parker Kelley, Michelle Matvey, Josh Woolley MD/PhD Ellen Bradley Winston Chiong @[email protected] in JAMA Psychiatry

MAPS The New York Times x.com/RecoveryDoctor…

My personal response to the propagandistic & defamatory New York Times article on @Psymposia, which violated the Times' editorial standards. This transparently partisan attack politicized whistleblowers to appeal to the Trump administration on behalf of a pharmaceutical company.

Cautious Optimism, Lingering Questions: Researchers React to Compass’ Phase 3 Psilocybin Results We spoke with 内田裕之 (Hiroyuki Uchida), Helena Aicher, Boris D Heifets, Max Wolff, Josh Woolley MD/PhD, and others for our researchers react piece. psychedelicalpha.com/news/cautious-…